SYS-CON MEDIA Authors: Gilad Parann-Nissany, RealWire News Distribution

News Feed Item

Easton Pharmaceutical, Inc. Analyst Report and Medical Marijuana Initiatives - by BrokerBank Securities, Inc.

NEW YORK, Feb. 10, 2014 /PRNewswire/ -- Easton Pharmaceutical, Inc. (PINKSHEETS: EAPH) is a company that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products. Easton Pharmaceuticals product "VIORRA", is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder).  The world market demand for this female condition is conservatively estimated to be in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized Safe ingredients.

The potential market for an FASD treatment could rival the well-known treatment for male erectile dysfunction, Viagra. Viagra, known generically as sildenafil citrate, hit the market in 1998. Viagra's manufacturer, Pfizer, increase bottom-line profits by 38 percent for this product alone. In its first year, 2.7 million prescriptions were filled, and the company posted $411 million in sales, according to reports at the time. Today, Viagra,  is arguably the best selling drug of all time, and has annual sales of $5 billion and that does not include the plethora of generic sildenafil citrate being manufactured and sold all over the world.

Easton's  other products are focused on cancer and other health issues related towards, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company's gel formulation is thought to be an innovative and unique transdermal delivery system.

EAPH has announced progress toward a product launch date for VIORRA in Mexico. In other new development, Easton Pharmaceuticals has executed and closed on an agreement regarding its Medical Marijuana Initiatives. Another formal announcement is expected within a few days as well as possible other HEMP related OTC products Easton has been formulating.

Get the latest information on the VIORRA and marijuana initiatives at EAPH by following the link: http://bit.ly/AnalystReportEAPH copy and paste to browser may be required

About SmallCapStreet.com

SmallCapStreet.com is the leading source for micro-cap and small-cap stock reports and analysis. We work closely with the very best Chartered Financial Analysts and financial writers in the industry to bring accurate and useful information to the investment community.

For the Stock Profiles Text Keyword "Street" to 25827 to Receive Instant Mobile Alerts

1. BrokerBank Securities, Inc. is the party responsible for issuing the press release. Small Cap Street, LLC is the party responsible for hosting the full analyst report on SmallCapStreet.com. Marc Bonacci, Chief Analyst is the author of research report.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Marc Bonacci, Chief Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted to increase awareness to the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcapstreet.com.

5.  For any urgent concerns or inquiries, please contact us at compliance@smallcapstreet.com.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Marc Bonacci, Chief Analyst. An outsourced research services provider represented by Marc Bonacci, Chief Analyst, has written and reviewed the information in this article or report. BrokerBank Securities, Inc. or Small Cap Street, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Marc Bonacci, Chief Analyst.

NOT FINANCIAL ADVICE

BrokerBank Securities, Inc. or Small Cap Street, LLC makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

EAPH has not compensated BrokerBank Securities, Inc. Small Cap Street, LLC or Marc Bonacci, Chief Analyst, for the creation or dissemination of this press release. BrokerBank Securities, Inc. or Small Cap Street, LLC. is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by BrokerBank Securities, Inc. or Small Cap Street, LLC. whatsoever for any direct, indirect or consequential loss arising from the use of this document. BrokerBank Securities, Inc. or Small Cap Street, LLC. expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. BrokerBank Securities, Inc. or Small Cap Street, LLC. does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.